Sensei Biotherapeutics (NASDAQ:FTH) Shares Up 5.4% – Time to Buy?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s stock price rose 5.4% during trading on Tuesday . The stock traded as high as $33.87 and last traded at $34.5250. 9,984 shares changed hands during trading, a decline of 95% from the average session volume of 211,519 shares. The stock had previously closed at $32.77.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They set an “outperform” rating and a $57.00 target price for the company. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Wall Street Zen raised shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Finally, Oppenheimer started coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Sensei Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Stock Up 5.1%

The firm has a fifty day moving average price of $28.72. The stock has a market capitalization of $889.67 million, a PE ratio of -0.24 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, research analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current year.

Insider Activity

In other news, CFO Brian C. Stephenson bought 9,391 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was purchased at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the acquisition, the chief financial officer directly owned 26,804 shares of the company’s stock, valued at $700,388.52. This trade represents a 53.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 22nd. The shares were bought at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 49,494 shares of company stock worth $1,188,822 in the last quarter. 7.00% of the stock is owned by insiders.

Institutional Trading of Sensei Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its holdings in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after buying an additional 1,100 shares during the period. Bank of America Corp DE boosted its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics in the first quarter valued at $4,188,000. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics in the second quarter valued at about $3,610,000. Finally, Vivo Capital LLC bought a new stake in shares of Sensei Biotherapeutics in the first quarter valued at about $22,758,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.